End of an era in antibiotic blockbusters as FDA approves Levaquin generics
This article was originally published in Scrip
Executive Summary
The US Food and Drug Administration has approved the first generic versions of Johnson & Johnson’s blockbuster antibacterial drug Levaquin (levofloxacin). Twelve companies, including generic heavyweights Mylan and Teva Pharmaceutical Industries, had applied to market generic versions of the drug in the lucrative US market.